» Articles » PMID: 32497632

Potential Therapeutic Targets for Combating SARS-CoV-2: Drug Repurposing, Clinical Trials and Recent Advancements

Overview
Journal Life Sci
Publisher Elsevier
Date 2020 Jun 5
PMID 32497632
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

The present pandemic of SARS-CoV-2 has been a tough task for the whole world to deal with. With the absence of specific drugs or vaccines against SARS-CoV-2, the situation is very difficult to control. Apart from the absence of specific therapies, the lack of knowledge about potential therapeutic targets and individual perception is adding to the complications. The present review describes the novel SARS-CoV-2 structure, surface proteins, asymptomatic and symptomatic transmission in addition to the genotype and phenotype of SARS-CoV-2 along with genetic strains and similarity between SARS, MERS and SARS-CoV-2. Therapeutic strategies such as inhibition of the endocytic pathway and suppressing RNA polymerase activity by metal ions, which could be quite beneficial for controlling COVID-19, are outlined. The drug repurposing for SARS-CoV-2 is discussed in detail along with therapeutic classes such as antivirals, antibiotics, and amino quinolones and their probable role in suppressing SARS-CoV-2 with reference to case studies. The ongoing clinical trials both with respect to drug repurposing and vaccines are summarized along with a brief description. The recent advancements and future perspective of ongoing research for therapy and detection of SARS-CoV-2 are provided. The review, in brief, summarizes epidemiology, therapy and the current scenario for combating SARS-CoV-2.

Citing Articles

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.

Barghash R, Gemmati D, Awad A, Elbakry M, Tisato V, Awad K Molecules. 2024; 29(23.

PMID: 39683724 PMC: 11643501. DOI: 10.3390/molecules29235564.


Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.

Mia M, Howlader M, Akter F, Hossain M Clin Pathol. 2024; 17:2632010X241263054.

PMID: 39070952 PMC: 11282570. DOI: 10.1177/2632010X241263054.


Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.

Sarfraz A, Sarfraz Z, Bano S, Sarfraz M, Jaan A, Minhas A J Community Hosp Intern Med Perspect. 2024; 14(2):58-66.

PMID: 38966504 PMC: 11221457. DOI: 10.55729/2000-9666.1308.


3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials.

Amorim V, Soares E, de Almeida Ferrari A, Merighi D, de Souza R, Guzzo C Viruses. 2024; 16(6).

PMID: 38932137 PMC: 11209289. DOI: 10.3390/v16060844.


ML241 Antagonizes ERK 1/2 Activation and Inhibits Rotavirus Proliferation.

Wang J, Hu X, Wu J, Lin X, Chen R, Lu C Viruses. 2024; 16(4).

PMID: 38675964 PMC: 11054276. DOI: 10.3390/v16040623.


References
1.
Vashist S . In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics (Basel). 2020; 10(4). PMC: 7235801. DOI: 10.3390/diagnostics10040202. View

2.
Zeng L, Yang J, Liu S . Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs. 2016; 26(1):63-73. DOI: 10.1080/13543784.2017.1269170. View

3.
Cure E, Cumhur Cure M . Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr. 2020; 14(4):405-406. PMC: 7195078. DOI: 10.1016/j.dsx.2020.04.024. View

4.
Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X . Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013; 57(4):1743-55. PMC: 3623363. DOI: 10.1128/AAC.02282-12. View

5.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View